You are here: Industry Insights > GIST

News List

CStone announces updated results for AYVAKIT(R) (avapritinib) in Chinese patients with advanced GIST at ESMO World Congress on Gastrointestinal Cancer 2021 prnasia
July 08, 2021
CStone Pharmaceuticals, a leading biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology therapies and precision medicines, presented results from a phase 1/2 clinical study of AYVAKIT® ...
CStone Announces Acceptance of New Drug Application in Hong Kong, S.A.R., China for Avapritinib for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumor prnasia
May 12, 2021
CStone Pharmaceuticals, a leading biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology therapies and precision medicines, today announced the acceptance of the company's new drug application ...
CStone Announces China NMPA New Drug Approval of Precision Therapy AYVAKIT® (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tum prnasia
March 31, 2021
CStone Pharmaceuticals, a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies and precision medicines, today announces that the National Medical Products Administration (NMPA) of China has ...
New Drug for Gastrointestinal Stromal Tumours (GIST) to be Launched in Australia, New Zealand and South East Asia Following Distribution Agreement prnasia
November 06, 2020
A NEW therapy to treat advanced gastrointestinal stromal tumours (GIST) will be available to patients in Australia, New Zealand and in some parts of South East Asia, following an exclusive distribution agreement.
CStone Announces Preliminary Results from a Bridging Study of Avapritinib in Chinese Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors at the 2020 CSCO Annual Meeting prnasia
September 27, 2020
CStone Pharmaceuticals (SUZHOU) Co., Ltd. presented positive results at the 2020 Chinese Society of Clinical Oncology (CSCO) Annual Meeting from a phase I/II bridging study in China evaluating avapritinib in patients with unresectable or metastatic ...
FDA Approves Ripretinib for Advanced Gastrointestinal Stromal Tumor americanpharmaceuticalreview
May 28, 2020
The Food and Drug Administration (FDA) approved ripretinib (QINLOCK, Deciphera Pharmaceuticals), for adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
Deciphera gets FDA nod for Qinlock to treat fourth-line gastrointestinal stromal tumour pharmaceutical-business-review
May 20, 2020
Deciphera Pharmaceuticals has secured approval from the US Food and Drug Administration (FDA) for its Qinlock (ripretinib) to treat fourth-line gastrointestinal stromal tumour (GIST).
Blueprint Medicines Receives CRL for Avapritinib americanpharmaceuticalreview
May 20, 2020
Blueprint Medicines announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the new drug application of avapritinib.
FDA approves the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors worldpharmanews
January 14, 2020
The U.S. Food and Drug Administration approved Ayvakit (avapritinib) for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) gastrointestinal stromal tumor (GIST
FDA approves Ayvakit, the first targeted gastrointestinal stromal tumour treatment europeanpharmaceuticalreview
January 13, 2020
The US Food and Drug Administration (FDA) has approved the kinase inhibitor Ayvakit (avapritinib) for the treatment of unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring platelet-derived growth factor receptor alpha (PDGFRA) exo

Previous page 1 2 Next page